(Albany, NewYork) – September 10 2026: DelveInsight’s “Obesity Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Obesity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obesity Market Forecast
Some of the key facts of the Obesity Market Report:
In 2025, the Obesity Treatment Market Size in the US was around USD 13 billion. This figure is expected to grow significantly with the introduction of emerging therapies by 2036.
In September 2026, The global weight-loss drug market is entering a significant new phase. Following the success of injectable GLP-1 therapies in reshaping obesity treatment, pharmaceutical companies are increasingly focusing on developing oral alternatives that offer patients a more convenient option. This transition is already gaining momentum. Novo Nordisk’s oral Wegovy, featuring semaglutide, was launched in the United States in January 2026 after receiving FDA approval in December 2025. Eli Lilly soon joined the oral obesity-treatment race with Foundayo (orforglipron), which secured U.S. FDA approval in April 2026 and became available shortly thereafter.
In July 2026, Novo Nordisk has announced that FDA-approved Wegovy® (semaglutide) is now available through the Medicare GLP-1 Bridge, a new access initiative designed to expand treatment availability for millions of older adults living with obesity. Wegovy is the only weight management therapy proven to reduce the risk of major adverse cardiovascular events including heart attack, stroke, and cardiovascular death—in adults with obesity and established cardiovascular disease. This benefit is particularly significant for individuals aged 65 years and older, who face a higher prevalence of both obesity and heart disease. Under the program, eligible Medicare beneficiaries can obtain Wegovy injections or oral formulations with a $50 monthly copay, with the access program available through the end of 2027.
In December 2025, Novo Nordisk announced that it has submitted a New Drug Application (NDA) to the US FDA for once-weekly CagriSema, a fixed-dose injectable combination of cagrilintide 2.4 mg and semaglutide 2.4 mg. The therapy is intended for use alongside a reduced-calorie diet and increased physical activity to support long-term weight loss and maintenance in adults with obesity or overweight who have at least one weight-related comorbidity. CagriSema combines a long-acting amylin analogue with a GLP-1 receptor agonist, and if approved, it would represent the first injectable treatment to integrate these two mechanisms in a single formulation.
In May 2025, ICON plc (NASDAQ: ICLR), a global leader in clinical research driven by healthcare intelligence, has published the results of a survey involving 155 biotech and pharmaceutical professionals from the US and Europe. The survey focused on multi-indication cardiometabolic research and development (R&D) for therapies targeting obesity and its related conditions. Multi-indication studies refer to clinical trials that evaluate the effectiveness of a treatment across multiple diseases or conditions.
In April 2025, Corxel Pharmaceuticals has obtained clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application, allowing the initiation of a randomized Phase II trial in the US for CX11, an oral small molecule GLP-1 receptor agonist (GLP-1 RA) aimed at treating obesity. This double-blind, placebo-controlled study will evaluate the safety and effectiveness of the once-daily therapy in individuals who are overweight or obese. Corxel plans to begin enrolling participants in the second quarter of this year, with topline results anticipated in the first half of 2026.
In March 2025, Zealand Pharma completed enrollment for its global, randomized Phase IIb ZUPREME-1 trial, which is evaluating petrelintide, a long-acting amylin analogue, in people with obesity or overweight and associated comorbidities. This placebo-controlled, multi-center, parallel-group study aims to compare the once-weekly subcutaneous injection of petrelintide to a placebo in terms of safety, tolerability, and impact on body weight.
In January 2025, Novo Nordisk’s high-dose formulation of Wegovy (semaglutide) has demonstrated enhanced weight loss benefits while maintaining a favorable safety and tolerability profile. In the Phase IIIb STEP UP trial, the 7.2mg dose of Wegovy showed statistically significant and superior weight reduction at week 72. The study involved 1,407 adults with obesity who were randomized to receive once-weekly injections alongside lifestyle modification support.
In January 2025, Viking Therapeutics has initiated a Phase II clinical trial for VK2735, an oral tablet developed to address metabolic conditions like obesity. The VENTURE-Oral Dosing Trial is a randomized, double-blind, placebo-controlled, multi-center study designed to evaluate the safety, tolerability, and effectiveness of the drug in promoting weight loss over a 13-week period.
The Obesity Treatment Market Size of EU4 and the UK was estimated to be more than USD 2.5 billion in 2025.
Among EU4 and the UK, Germany accounted for the highest market share with approximately USD 720 million in 2025.
In 2025, the Obesity Treatment Market Size was approximately USD 70 million in Japan, which is anticipated to increase during the forecast period (2026–2036).
According to DelveInsight’s analysis, the United States accounted for approximately 60% of the total prevalent obesity cases across the 7MM in 2025, reflecting its substantial disease burden and positioning the US as the largest market within the assessed geographies.
In 2025, approximately 7 million children aged 5–19 years in the US were living with obesity, underscoring the significant pediatric disease burden and the growing need for effective prevention and treatment strategies targeting younger populations.
Among the EU4 and the UK, Germany recorded the highest number of prevalent obesity cases in 2025, at approximately 18 million. The large affected population highlights Germany as a key market for obesity management and represents considerable potential for the adoption of effective pharmacological therapies.
Japan is witnessing a gradual increase in treated obesity cases, supported by growing disease awareness and the expanding availability of treatment options. In 2025, Japan had approximately 150,000 treated adult cases and around 180 treated pediatric cases. The continued increase in treated populations is expected to support greater demand for obesity therapies as diagnosis, treatment-seeking, and access to pharmacological interventions improve.
Key Obesity Companies: Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others
Key Obesity Therapies: IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others
The Obesity market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Obesity pipeline products will significantly revolutionize the Obesity market dynamics.
Obesity Overview
Obesity is a medical condition characterized by excessive body fat accumulation, which can negatively impact health. It is typically measured using the Body Mass Index (BMI), with a BMI of 30 or higher indicating obesity. This condition increases the risk of various health issues, including heart disease, diabetes, hypertension, and certain cancers. Obesity can result from multiple factors, such as poor diet, lack of physical activity, genetics, and hormonal imbalances. Effective management includes lifestyle changes, medical treatments, and, in some cases, surgical interventions to improve overall health and reduce associated risks.
Get a Free sample for the Obesity Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market
Obesity Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Obesity Epidemiology Segmentation:
The Obesity market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:
Total Prevalence of Obesity
Prevalent Cases of Obesity by severity
Gender-specific Prevalence of Obesity
Diagnosed Cases of Episodic and Chronic Obesity
Download the report to understand which factors are driving Obesity epidemiology trends @ Obesity Epidemiology Forecast
Obesity Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Obesity market or expected to get launched during the study period. The analysis covers Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Obesity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Obesity Therapies and Key Companies
IMCIVREE (setmelanotide): Rhythm Pharmaceuticals
ZEPBOUND (tirzepatide): Eli Lilly and Company
Survodutide (BI 456906): Boehringer Ingelhium
DD03: D&D Pharmatech
AX-0601: ProQR Therapeutics
NPM 139: Nano Precision Medical
BK-1701: Bukwang Pharmaceutical
CBW-520: Caliway Biopharmaceutics
YH34160: Yuhan
TERN-601: Terns Pharmaceuticals
Thermostem: BioRestorative Therapies
SCO-267: SCOHIA PHARMA
CT-181: Click Therapeutics
HM15136: Hanmi Pharmaceuticals
NNC0480-0389: Novo Nordisk
EMP-16: Empros Pharma
CT-868: Carmot Therapeutics
Tirzepatide: Eli Lilly and Company
Semaglutide Oral: Novo Nordisk
Discover more about therapies set to grab major Obesity market share @ Obesity Treatment Landscape
Obesity Market Drivers
Rising global prevalence of obesity across adult and pediatric populations, increasing demand for effective treatment options.
Growing awareness of obesity as a chronic disease rather than a lifestyle issue, supporting long-term pharmacological management.
Strong R&D investments by leading pharmaceutical companies in GLP-1, dual and triple agonists, and combination therapies.
Regulatory approvals of novel anti-obesity drugs such as semaglutide and tirzepatide, driving rapid market uptake.
Increasing healthcare expenditure and improved reimbursement in developed markets.
Expansion of digital health, weight-management programs, and telemedicine supporting treatment adherence.
Obesity Market Barriers
High cost of branded obesity medications, limiting affordability and access in many regions.
Limited insurance coverage and reimbursement challenges, particularly in emerging markets.
Safety concerns and long-term tolerability issues associated with chronic obesity drug use.
Stigma and low treatment-seeking behavior among obese individuals
Strict regulatory requirements and lengthy clinical trial timelines for new therapies.
Supply constraints and manufacturing challenges for high-demand injectable treatments.
Scope of the Obesity Market Report
Study Period: 2022–2036
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
Obesity Market Dynamics: Obesity market drivers and Obesity market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Obesity Unmet Needs, KOL’s views, Analyst’s views, Obesity Market Access and Reimbursement
To know more about Obesity companies working in the treatment market, visit @ Obesity Clinical Trials and Therapeutic Assessment
Table of Contents
1. Obesity Market Report Introduction
2. Executive Summary for Obesity
3. SWOT analysis of Obesity
4. Obesity Patient Share (%) Overview at a Glance
5. Obesity Market Overview at a Glance
6. Obesity Disease Background and Overview
7. Obesity Epidemiology and Patient Population
8. Country-Specific Patient Population of Obesity
9. Obesity Current Treatment and Medical Practices
10. Obesity Unmet Needs
11. Obesity Emerging Therapies
12. Obesity Market Outlook
13. Country-Wise Obesity Market Analysis (2022–2036)
14. Obesity Market Access and Reimbursement of Therapies
15. Obesity Market Drivers
16. Obesity Market Barriers
17. Obesity Appendix
18. Obesity Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679 Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
